

Cambridge University Press

978-0-521-76431-5 - Ethics and the Business of Biomedicine

Edited by Denis G. Arnold

[Table of Contents](#)[More information](#)*Contents*

<i>List of figures</i>	<i>page</i> vii
<i>List of contributors</i>	viii
<i>Acknowledgements</i>	x
Introduction	I
1 Medicine and the market <i>Daniel Callahan</i>	20
2 Broken promises: do business-friendly strategies frustrate just healthcare? <i>Norman Daniels</i>	35
3 Are patents an efficient and internationally fair means of funding research & development for new medicines? <i>Paul T. Menzel</i>	62
4 The exploitation of the economically disadvantaged in pharmaceutical research <i>Tom L. Beauchamp</i>	83
5 The dangers of detailing: how pharmaceutical marketing threatens healthcare <i>Jason E. Hubbard</i>	103
6 The ethics of direct-to-consumer pharmaceutical advertising <i>Denis G. Arnold</i>	131
7 Industry-funded bioethics and the limits of disclosure <i>Carl Elliott</i>	150
8 Two cheers for the pharmaceutical industry <i>Richard T. De George</i>	169

Cambridge University Press

978-0-521-76431-5 - Ethics and the Business of Biomedicine

Edited by Denis G. Arnold

Table of Contents

[More information](#)

vi

*Contents*

9	The third face of medicine: ethics, business and challenges to professionalism <i>Mary Rorty, Patricia Werhane, and Ann Mills</i>	198
10	Theoretical foundations for organizational ethics: developing norms for a new kind of healthcare <i>George Khushf</i>	220
11	A crisis in medical professionalism: time for Flexner II <i>Daniel Wikler</i>	249
	<i>Bibliography</i>	260
	<i>Index</i>	283